Online inquiry

IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5118MR)

This product GTTS-WQ5118MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ5118MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3002MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ851MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ1954MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ11533MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MGA031
GTTS-WQ3053MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ699MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ1728MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ12382MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW